Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeJun Zhou, F. Stephen Hodi, Xiaoyun Liao et al.|Cancer Immunology Research|2017Cited by 363
Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical OutcomesXinqi Wu, F. Stephen Hodi, Jingjing Li et al.|Cancer Immunology Research|2017Cited by 68